Compare CUBI & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CUBI | EVO |
|---|---|---|
| Founded | 1994 | 1993 |
| Country | United States | Germany |
| Employees | 869 | 4553 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 994.5M |
| IPO Year | N/A | N/A |
| Metric | CUBI | EVO |
|---|---|---|
| Price | $76.47 | $2.80 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 1 |
| Target Price | ★ $85.00 | $7.00 |
| AVG Volume (30 Days) | ★ 275.2K | 26.8K |
| Earning Date | 04-23-2026 | 04-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $24.95 | $1.37 |
| Revenue Next Year | $9.50 | $10.05 |
| P/E Ratio | $11.78 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $50.25 | $2.31 |
| 52 Week High | $82.56 | $4.42 |
| Indicator | CUBI | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 54.86 | 47.23 |
| Support Level | $71.61 | $2.63 |
| Resistance Level | $79.11 | $3.82 |
| Average True Range (ATR) | 1.82 | 0.07 |
| MACD | 0.32 | -0.02 |
| Stochastic Oscillator | 62.70 | 44.88 |
Customers Bancorp Inc is a bank holding company conducting banking activities through its wholly owned subsidiary, Customers Bank. The Bank provides commercial and consumer customers the stability of a regulated financial institution supported by risk management. It serves commercial and corporate businesses nationwide, including healthcare, real estate, specialty finance, fund finance, technology and venture capital banking, mortgage finance and commercial equipment financing, and provides payments and treasury services. The Bank also serves consumers through its branch network, offering residential mortgages and personal loan and deposit products, including Banking-as-a-Service, with services delivered predominantly in Southeastern and Central Pennsylvania, New York, and other states.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.